Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer

Laura M. Spring, Hyo Han, Minetta C. Liu, Erika Hamilton, Hanna Irie, Cesar A. Santa-Maria, James Reeves, Peng Pan, Ming Shan, Yongqiang Tang, Julie R. Graham, Sebastien Hazard, Leif W. Ellisen, Steven J. Isakoff

Research output: Contribution to journalArticlepeer-review

Abstract

This single-arm pilot study (NCT03329937) evaluated neoadjuvant niraparib antitumor activity and safety in patients with localized HER2-negative, BRCA-mutated breast cancer. Twenty-one patients received niraparib 200 mg once daily in 28-day cycles. After 2 cycles, tumor response (≥30% reduction from baseline) by MRI was 90.5% and 40.0% (6 of 15) of patients who received only niraparib (2–6 cycles) had pathological complete response; no new safety signals were identified. High niraparib intratumoral concentration was observed.

Original languageEnglish (US)
JournalNature Cancer
DOIs
StateAccepted/In press - 2022

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer'. Together they form a unique fingerprint.

Cite this